In a regulatory filing, Marvai Lifesciences CEO Brend Brust disclosed the purchase of 216,212 class A common shares of the company on November 13 at a price of $3.25 per share, or a total consideration of $702,689.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Earnings Call: Mixed Signals
- Maravai Lifesciences price target lowered to $4 from $5 at Stifel
- Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts
- Maravai LifeSciences Reports Q3 2025 Financial Results
- Maravai Lifesciences reports Q3 adjusted EPS (8c), consensus (8c)